Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:1
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (66.7%)Phase 2
1 (33.3%)Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
Phase 4
Completed
- Conditions
- Psoriasis Vulgaris
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Dermatology Consulting Services, PLLC
- Target Recruit Count
- 10
- Registration Number
- NCT06042647
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
Phase 4
Completed
- Conditions
- Scalp Psoriasis
- Interventions
- Drug: 0.045% Tazarotene/0.01% Halobetasol Lotion
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Dermatology Consulting Services, PLLC
- Target Recruit Count
- 20
- Registration Number
- NCT05872256
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Dermatology Consulting Services, PLLC
- Target Recruit Count
- 40
- Registration Number
- NCT05278624
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
News
No news found